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Metabolic disorders associated with obesity and cardiometabolic disorders are
worldwide epidemic. Among the different environmental factors, the gut microbiota
is now considered as a key player interfering with energy metabolism and host
susceptibility to several non-communicable diseases. Among the next-generation
beneficial microbes that have been identified, Akkermansia muciniphila is a promising
candidate. Indeed, A. muciniphila is inversely associated with obesity, diabetes,
cardiometabolic diseases and low-grade inflammation. Besides the numerous
correlations observed, a large body of evidence has demonstrated the causal beneficial
impact of this bacterium in a variety of preclinical models. Translating these exciting
observations to human would be the next logic step and it now appears that several
obstacles that would prevent the use of A. muciniphila administration in humans have
been overcome. Moreover, several lines of evidence indicate that pasteurization of
A. muciniphila not only increases its stability but more importantly increases its efficacy.
This strongly positions A. muciniphila in the forefront of next-generation candidates for
developing novel food or pharma supplements with beneficial effects. Finally, a specific
protein present on the outer membrane of A. muciniphila, termed Amuc_1100, could be
strong candidate for future drug development. In conclusion, as plants and its related
knowledge, known as pharmacognosy, have been the source for designing drugs over
the last century, we propose that microbes and microbiomegnosy, or knowledge of our
gut microbiome, can become a novel source of future therapies.
Keywords: Akkermansia muciniphila, obesity, diabetes mellitus, type 2, probiotics and prebiotics, gut barrier
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INTRODUCTION
Overweight and obesity have reached epidemic proportions with more than 600 million of
adults and 100 million children of the world’s population suffering from obesity (GBD 2015
Obesity Collaborators et al., 2017). Obesity predisposes to the development of type 2 diabetes
and cardiovascular diseases. These two pathologies are part of the metabolic syndrome that is also
becoming major problem in public health (Abdelaal et al., 2017; Ajala et al., 2017). Gut microbes
play an important role in the regulation of host metabolism and low-grade inflammation (Hartstra
et al., 2015; Marchesi et al., 2016; Cani, 2017). The perturbation of the composition and the
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activity of the gut microbiota, also known as dysbiosis, is thought
to be involved in the emergence of the metabolic syndrome
(Wen and Duffy, 2017). Nowadays, numerous studies have
demonstrated that our dietary habits strongly influence the
composition and function of the gut microbiota and eventually
may contribute to the onset or the protection against metabolic
disorders (David et al., 2014; Korpela et al., 2014; Salonen et al.,
2014; Carmody et al., 2015; Zeevi et al., 2015; Cani and Everard,
2016; Thaiss et al., 2016).
Well documented among the potential ways to affect the
gut microbiota, is the consumption of selected microbes that
are marketed as probiotics defined as “live microorganisms
that when administered in adequate amounts confer a health
benefit on the host” (Hill et al., 2014). It is worth noting
that the current majority of probiotics sold on the market
include mainly microorganisms from the genera Lactobacillus
and Bifidobacterium (Douillard and de Vos, 2014). However,
other ways such as the consumption of prebiotics have gained
considerable attention over the last 20 years (Roberfroid
et al., 2010). The prebiotic concept, discovered in Gibson
and Roberfroid (1995), has led to a great number of dietary
supplements that is an important growth market. The definition
of prebiotic is now widely used and has been recently revised as
“a substrate that is selectively utilized by host microorganisms
conferring a health benefit” (Gibson et al., 2017). Thus,
nutritional components that escape the digestion in the upper
alimentary tract may have an impact on the gut microbiota by
modulating some members of the gut microbiota its composition
and its activity. However, the concept of prebiotic has not
yet revealed all its secrets. In spite of numerous discoveries
of molecular mechanisms explaining how prebiotics and the
gut microbiota interact with the host, it remains difficult to
identify the bacterial candidate(s) involved in the beneficial




MICROBE: FOCUS ON THE
IDENTIFICATION OF Akkermansia
muciniphila
Akkermansia muciniphila is one of the most abundant single
species in the human intestinal microbiota (0.5–5% of the total
bacteria) and has been isolated and characterized as a mucin-
utilizing specialist in 2004 by Muriel Derrien in her Ph.D.
research at Wageningen University (Derrien et al., 2004; Collado
et al., 2007). This discovery was initiated by the notion that
the human body produces its own “prebiotics” or microbial
substrates, namely mucus, an abundant glycoprotein that is
specifically produced and degraded in the colon (Ouwehand
et al., 2005). While germ-free mouse experiments showed
that A. muciniphila showed immune and metabolic signaling,
specifically in the colon, the exact functions of this unusual
microbe remained enigmatic (Derrien et al., 2008, 2011).
Further indications for the function of A. muciniphila were
subsequently determined in other prebiotic studies using inulin-
type fructans that were initially characterized as bifidogenic
compounds able to increase the abundance of Bifidobacterium
spp. (Gibson and Roberfroid, 1995). Thanks to the development
of novel culture-independent techniques, we decided to revise
in depth the impact of such kind of prebiotics on the overall
microbial community in mice. Therefore, in search of potential
novel bacterial candidates, we combined different techniques
(phylogenetic microarray, high-throughput sequencing, gradient
denaturation gel and qPCR), which allowed us to analyze and
to compare all the bacteria that were present in the intestinal
microbiota. The first surprise was to discover that more than
100 different taxa were affected by prebiotics (Everard et al.,
2011; Everard et al., 2014). Among these bacteria, we found that
the relative abundance of A. muciniphila increased more than
100-fold following the ingestion of prebiotics thereby reaching
the abundance of up to 4.5% under high-fat diet (Everard et al.,
2014), whereas this effect was lower under normal chow diet
(0.09–2.5%) depending on the model (Everard et al., 2011, 2014).
It is worth noting that these findings are confirmed in different
set of experiments (Everard et al., 2013; Liu et al., 2016; Reid
et al., 2016; Catry et al., 2017; Zhu et al., 2017). Interestingly, we
and others discovered that A. muciniphila was less abundant in
the intestinal microbiota of both genetic and diet-induced obese
and diabetic mice (Everard et al., 2011, 2013, 2014; Schneeberger
et al., 2015; Leal-Diaz et al., 2016; Ojo et al., 2016; Song et al.,
2016; Singh et al., 2017), however, few studies reported in mice
an increased abundance of A. muciniphila upon the ingestion
of a high-fat high sucrose diet (Anhe et al., 2015; Carmody
et al., 2015). It has also been largely demonstrated that inulin-
type fructans feeding improves metabolic disorders associated
with obesity, including a decreased fat mass, insulin resistance,
lower liver steatosis and a reinforcement of the gut barrier
(Figure 1) (Cani et al., 2004, 2006, 2009; Maurer et al., 2010;
Everard et al., 2011; Pachikian et al., 2012; Greer et al., 2016).
Importantly, in humans the abundance of A. muciniphila was
decreased in several pathological situations such as obesity, type
2 diabetes, inflammatory bowel diseases, hypertension and liver
diseases (Png et al., 2010; Belzer and de Vos, 2012; Zhang et al.,
2013; Dao et al., 2015; Yassour et al., 2016; Grander et al.,
2017; Li et al., 2017). Conversely, antidiabetic treatments, such
as metformin administration and bariatric surgery were both
found to be associated with a marked increase in the abundance
of A. muciniphila (Figure 1) (Shin et al., 2014; Forslund et al.,
2015; de la Cuesta-Zuluaga et al., 2017). Therefore, a large body
of evidence suggested that A. muciniphila may contribute to
protect from specific metabolic disorders and cardiometabolic
risk factors associated with a low-grade inflammatory tone.
ADMINISTRATION OF Akkermansia
muciniphila: MULTIPLE EFFECTS ON
THE GUT AND BEYOND
Inspired by the numerous indications that the relative levels of
A. muciniphila decreased during obesity and metabolic disorders
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FIGURE 1 | Effects of A. muciniphila and derived products on host metabolism. A. muciniphila has been found to be lower in several conditions such as during
obesity, diabetes, intestinal inflammation, liver diseases, or chronic alcohol consumption. This is associated with an altered gut barrier function leading to an
increased plasma LPS levels and eventually triggering low grade inflammation and metabolic disorders. A. muciniphila alive or pasteurized as well as Amuc_1100
has been shown to restore gut barrier function likely by acting on TLR2 and restoring appropriate tight junction expression. All these results are associated with an
increased mucus later thickness and an improvement of metabolic disorders. It is worth noting that an exploratory human investigation has shown that
A. muciniphila is apparently safe.
in mouse and man, we decided to study the causal link between
A. muciniphila and improvements in metabolism. This was done
by investigating the impact of a daily oral supplementation with
live A. muciniphila on the onset of obesity, diabetes and gut
barrier dysfunction in mice. We found that the administration of
live A. muciniphila at the dose of 2.108 bacterial cells per day was
partly protecting against diet-induced obesity in mice (Everard
et al., 2013). Indeed, mice showed a 50% lower body weight
gain when treated with live A. muciniphila without altering
neither their dietary food intake nor the elimination of dietary
fats in fecal matter. This protection was mirrored by two times
less visceral and subcutaneous fat mass (Figure 1), but also
by increased markers of fatty acid oxidation in the adipose
tissue (Everard et al., 2013). In addition, animals receiving live
A. muciniphila did no longer exhibited insulin resistance, nor
infiltration of inflammatory cells (CD11c) in the adipose tissue,
which is a key characteristic of obesity and associated low-grade
inflammation (Everard et al., 2013). Interestingly, most of all the
metabolic improvements observed following treatment with live
A. muciniphila were in the range as those observed following
oligofructose or inulin treatment (Cani et al., 2009; Dewulf et al.,
2011; Everard et al., 2011, 2014), although live A. muciniphila was
not affecting food intake behavior as do prebiotics like inulin and
oligofructose.
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Knowing that these metabolic features can be caused by
an increased plasma LPS level (i.e., metabolic endotoxemia)
or bacterial translocation (Cani et al., 2007; Amar et al.,
2011), we next investigated the gut barrier function by
measuring several markers. We observed that live A. muciniphila
prevented the development of metabolic endotoxemia, an effect
associated with the restoration of a normal mucus layer
thickness (Figure 1) (Everard et al., 2013). We also found that
administration of live A. muciniphila restored the endogenous
production of antimicrobial peptides. We then discovered that
live A. muciniphila increased the endogenous production of
specific bioactive lipids that belongs to the endocannabinoid
family and are known to have anti-inflammatory activities
and regulating the endogenous production of gut peptides
involved in glucose regulation and gut barrier, respectively,
glucagon-like peptide-1 and 2 (GLP-1 and GLP-2) (Cani
et al., 2016). It is worth noting that all these findings have
subsequently been confirmed by different groups and extended
to other specific disorders such as atherosclerosis, hepatic
inflammation and hypercholesterolemia (Shin et al., 2014; Li
et al., 2016; Shen et al., 2016; Grander et al., 2017; Plovier et al.,
2017).
Collectively all these data reinforce the assumption that
live A. muciniphila can be considered as a next-generation
beneficial microbe with the exceptional particularity that this
bacterium can act on numerous facets of the metabolic syndrome
and cardiometabolic disorders. Still, these discoveries have
raised different fundamental questions that will still have to be
studied in humans with the aim to generate new therapeutic
tools.
CROSSING THE BARRIER OF SPECIES:
FROM MICE TO MAN
Akkermansia muciniphila requires specific culture conditions
and complex animal-based medium (i.e., mucin from animal
source) and although it may respire under microaerophilic
conditions, the cells are relatively sensitive to oxygen
(Ouwerkerk et al., 2016). These properties complicate the
administration of A. muciniphila to human as to evaluate
its potential, hence limiting its therapeutic perspectives.
In order to solve this problem, a synthetic medium was
developed in order to allow the culture of A. muciniphila
with a high yield and devoid of compounds incompatible
with administration in humans (Plovier et al., 2017; Van
der Ark et al., unpublished data). Besides the successful
development of this synthetic medium, the previous
assessment of the efficacy of A. muciniphila were performed
with cells grown on a mucin-based medium. Therefore,
the bacteria cultured on the different media were tested
and compared. Interestingly, A. muciniphila retains its
effectiveness independently of the medium used, and as
previously observed, mice treated with the bacterium gained less
weight, exhibited an improved glucose tolerance, and insulin




In 2013, it was showed that the protective effects of A. muciniphila
disappeared when the bacterium was destroyed by using
autoclaving, a heat treatment that destroyes all the constituents
of bacteria and spores (Everard et al., 2013). As A. muciniphila
is a Gram-negative bacterium and hence no spore-former, we
were interested what the effects would be of pasteurization, a
milder heat inactivation method than autoclaving. Therefore, we
tested the impact of administrating pasteurized A. muciniphila
(30 min at 70◦C) cells on diet-induced metabolic disorders
in mice. Unexpectedly, this method of inactivation did not
abolish the effect of A. muciniphila but even exacerbated its
beneficial impact. Specifically, mice receiving the pasteurized
bacterium and the high-fat diet had a similar body weight
gain and fat mass than those observed in mice fed a control
diet. Again, these effects were independent of the food intake
but pasteurized A. muciniphila increased the loss of energy in
the feces of the treated mice, indicating a decrease in energy
absorption that could contribute to explain the lower weight
gain. Pasteurized A. muciniphila also strongly improved glucose
tolerance, hepatic insulin sensitivity, and completely blocked the
diet-induced metabolic endotoxemia. Although, the mechanisms
of action of the bacteria are not yet fully elucidated, it is known
that A. muciniphila express numerous highly abundant protein
on its outer membrane (Ottman et al., 2017). Among these
proteins, Amuc_1100, implicated in the formation of pili by
A. muciniphila, was one of the most abundant (Plovier et al.,
2017).
Akkermansia muciniphila: A GATE
KEEPER THAT DIALOGS WITH THE
INNATE IMMUNE SYSTEM
We previously found that A. muciniphila was able to restore
the expression of specific antimicrobial peptides (Everard et al.,
2013). However, Nucleotide oligomerization domain (NOD)-
like receptors (NLRs) and Toll-Like Receptors (TLRs) are a
specialized group of membrane and intracellular proteins that
play a critical role in the regulation of immunity and are
directly involved in the recognition of bacterial constituents by
the immune system. Therefore, we evaluated the potential of
A. muciniphila to activate different NOD and TLRs. Strikingly,
we found that the bacteria specifically interact with TLR2.
TLR2 has been shown to modulate intestinal homeostasis and
host metabolism (Caricilli et al., 2011; Brun et al., 2013),
thereby participating in the interactions between microbes and
host. In addition, to better characterize the interaction between
A. muciniphila and this receptor, we took advantage of genomic
and proteomic analyzes of the external membrane of the
bacterium, which may be exposed to host receptors (Ottman
et al., 2016). Among these proteins, Amuc_1100 was one of the
most abundant. This protein is implicated in the formation of pili
by A. muciniphila and thus could participate in the interaction
between the bacterium and TLR2. This hypothesis was further
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confirmed by showing that a version of the genetically engineered
protein (called Amuc_1100∗) was effectively activating TLR2
and with the same magnitude as A. muciniphila. In addition,
Amuc_1100∗ remained stable at the temperature used during
pasteurization, and could therefore contribute to the effects of
the pasteurized bacterium. Amuc_1100∗ was also able to replicate
almost all the effects of A. muciniphila alive or pasteurized
in high-fat diet fed mice. A. muciniphila, whether live or
pasteurized, and Amuc_1100∗ also decreased high cholesterol
levels induced by the high-fat diet. Conversely, the pasteurized
bacterium specifically also reduced the triglyceridemia of the
treated mice, reinforcing the idea that the pasteurization of
A. muciniphila reinforces its protective effects. A potential
mechanism explaining this could be the exposure of active
molecules by the heat treatments, including Amuc_1100, or
the inactivation of inhibitory compounds, or combinations
thereof.
FIRST ASSESSMENT OF Akkermansia
muciniphila IN HUMANS WITH
METABOLIC SYNDROME
As discussed earlier, A. muciniphila has various advantages as
compared to other beneficial microbes and specific probiotics, at
least in the context of the metabolic syndrome. A. muciniphila is
present in the human milk, is highly abundant in lean and non-
diabetic subjects, and is even highly increased upon metformin
treatment of gastric bypass surgery, and this without obvious
deleterious impact. This unique character does not preclude
the fact the human investigations and safety assessment must
be done. Hence, to become a putative future food supplement,
the safety must be tested. We evaluated the toxicity and the
emergence of possible side effects related to the administration
of A. muciniphila in humans (20 subjects) as part of an ongoing
clinical trial of individuals with metabolic syndrome (Plovier
et al., 2017). To this end, we analyzed relevant clinical parameters
related to liver, muscles and renal functions as well as markers
of immunity and inflammation in individuals who received
A. muciniphila daily for 2 weeks and then extended to 3 months.
Whatever the formulation of A. muciniphila (live at 109 and
1010 bacteria per day or pasteurized at 1010 bacteria per day),
no changes were observed for the markers tested after 2 weeks
or 3 months of daily administration. In addition, the frequency
of side effects reported by patients were similar in the different
groups. These first data indicate that A. muciniphila (active or
pasteurized) is tolerated in individuals with metabolic syndrome
and is likely not toxic.
While A. muciniphila is one of the handful of core microbes
identified in the intestinal microbiota of over 1000 human adults
(Shetty et al., 2017), the administration of its cells, either in live
or pasteurized form, in a dietary supplement may be subject to
regulatory frameworks that aim to safeguard the consumer. The
regulatory requirements relating to the use of live A. muciniphila
have recently been addressed (Gomez-Gallego et al., 2016). This
review summarized the recent comprehensive studies related to
A. muciniphila and its safety properties and provided criteria
be addressed when A. muciniphila cells are to be considered
as a novel food by the European Food Safety Authority in
Europe. One aspect that is relevant here and applies to other core
intestinal microbes as well, is the fact that most if not all healthy
subjects carry these anaerobes. So these have to be consumed
at some stage and in this context it is important to note that
A. muciniphila is present in early life microbiota and has been
detected in mothers’ milk (Collado et al., 2007, 2012; Derrien
et al., 2008; Jeurink et al., 2013; Ward et al., 2013). Another aspect
relates to the antibiotic resistance of A. muciniphila that has been
studied to some extent in healthy human subjects that carried
high levels of A. muciniphila-like bacteria and apparently were
sensitive to penicillin and tetracycline derivatives but resistant
to vancomycin (Dubourg et al., 2013). This was confirmed
in in vitro studies on the antibiotic resistance profile with
the type strain AmucT (Ouwerkerk Ph.D. Thesis Wageningen
University 2016). Moreover, inspection of the genome sequence
did not reveal antibiotic resistance genes that are linked to
known genetically transferrable elements (Gomez-Gallego et al.,
2016).
CONCLUSION
Since its discovery in 2004, numerous studies have mostly linked
the abundance of A. muciniphila with beneficial effects, and this
although very few exceptions exist in specific non-physiological
models (i.e., gnotobiotic models, specific immune double knock-
out models) (Seregin et al., 2017).
Nowadays, A. muciniphila is widely considered as a novel
potential candidate to improve metabolic disorders associated
with obesity, diabetes, liver diseases and cardiometabolic
disorders. Indeed, its administration has been shown to
profoundly reduce the development of such diseases.
Other important steps toward the development of
A. muciniphila as a next-generation beneficial microbe have
been successfully reached. First, the discovery that A. muciniphila
remained effective by being grown on a synthetic medium
compatible with administration in humans. Second, the
discovery that inactivation of the bacteria by pasteurization
improved its effects, and thus its stability and potential shelf
life. Third, the identification of a key mechanisms of interaction
between A. muciniphila and its host via the identification of
Amuc_1100, and last but not least; fourth, the demonstration
that A. muciniphila may be safely administered in the human
targeted population.
Finally, the pasteurized bacteria and the identification and the
isolation of bacterial constituents such as the relatively small 30-
kDa Amuc_1100 open the door to putative development of drugs
based on A. muciniphila-related product that could also target
pathologies such as type 1 diabetes, inflammatory bowel diseases
or diseases where the intestinal barrier function is compromised.
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